CRYOSTEM builds strong partnerships with academic and industrial players
To develop innovative network biobanking solutionsPartnerships
Ancillary studies, multi-disciplinary approaches, biobanking structures and biocollection : the CRYOSTEM network puts its biobanking expertise and know-how into a network for medical research and innovation projects in the field of immuno-hematology and cellular therapies.
With 28 CRB partners at the national level, the CRYOSTEM team is able to support academic and private actors in the creation and management of biological resource collections, by deploying dedicated networks and intervening at different levels :
- Study of operational feasibility: needs analysis, identification of CRBs and subcontractors ;
- Contracting ;
- Regulatory & ethics implementation: drafting information documents, assistance with drafting research protocols, management of regulatory procedures ;
- Operational implementation: harmonization of practices, document management, assistance with the development of management and centralization tools for biological and clinical data, management of training and authorization of staff from partner centers ;
- Project follow-up: monitoring of the collection, support for production, activity reports, management of subcontractors ;
- Valorization: management of biological resources provision, communication actions.
Find below the list of current partnerships, in which the CRYOSTEM network is involved for the creation of biocollections.
Indicators of the CRYOSTEM network biobanking activity
collaboration in development or under operational implementation
active collaborations (collection in progress)
List of collections
CRYO-LEA Biological Resources Collection
Enrichment of the L.E.A (Childhood and Adolescent Leukemia) cohort by the constitution of biological resources collection from blood or skin samples taken from patients treated respectively with chemotherapy (75%) or bone marrow transplant (25%) for childhood leukemia.
Objectives :
→ To identify predictive factors of long-term sequelae of chemotherapy or bone marrow transplant treatments in children with leukemia through the implementation of the GEN-LEA program (collaboration AP-HM / INSERM / CRYOSTEM / CNRGH). A first analysis has begun on almost 900 samples from the CRYO-LEA cohort on July 2022.
→ To offer personalized therapeutics
→ To improve patients quality of life
CRYO-LEA in figures* :
→ Number of patients included: 2 416
→ Number of samples available: 18 783
→ Number of partnering centers: 16
* as of 2023/08/31
Partner : L.E.A., prospective multicentric cohort of Child and Adolescent Leukemias
Investigators : Professeurs Gérard Michel, service pédiatrie et oncologie pédiatrique (Hôpital de la Timone) – Pascal Auquier, Faculté des Sciences Médicales et Paramédicales, UR3279 CERESS (Centre d’Etudes et de Recherches sur les Services de Santé et qualité de vie)
Promotor : Assistance Publique – Hôpitaux de Marseille (AP-HM)
Ancillary study of the Mac-Haplo-Mud clinical protocol
The purpose of the ancillary study is to build a biological resources collection from transplant patients included in the prospective randomized Phase III Mac-Haplo-Mud clinical trial.
Objectives :
The Mac-Haplo-Mud clinical protocol aims to compare haplo-identical* (half-compatible family donor with the patient for HLA genes) and pheno-identical (100% compatible family donor) grafts after reduced conditioning.
* The results of haplo-identical transplants with injection of a drug, Endoxan, are currently comparable in terms of overall survival and disease-free survival to transplants from an unrelated HLA-matched donor, but with less toxicity, including reduced rates of graft-versus-host disease (retrospective studies).
Mac-Haplo-Mud in figures* :
→ Number of patients included: 104
→ Number of samples taken: 831
→ Number of samples available: 2 366
→ Number of partnering centers: 22 (open to collection)
* as of 2023/09/30
Project coordinators : Pr Régis Peffault de Latour, Service d’Hématologie Greffe Hôpital Saint-Louis, Paris, Pr Marie-Thérèse Rubio, Service d’Hématologie du CHU Nancy
Promotor : Assistance Publique – Hôpitaux de Paris (AP-HP)
CeVi_CAR-T Biological Resources Collection
Creation of a perfectly annotated biological resources collection from blood samples of lymphoma patients treated with CAR-T cells. This collection, initiated in January 2020, is complementary to the lymph node samples provided by members of the CALYM network.
Objectives :
To provide teams with the necessary material to develop ambitious research programs consistent with the state of the art in order to respond to current issues:
→ To better identify and understand the biological mechanisms at the origin of CAR-T cell efficacy, but also of resistance to CAR-T cell treatments.
→ To have the epidemiological, clinical and biological information needed to optimize CAR-T strategies.
CeVi_CAR-T in figures*:
→ Number of partnering centers: 6
→ Number of patients included: 225
* as of 2023/08/31
Partner : The objective of the Institut Carnot CALYM is to promote innovation in lymphoma research and accelerate its transfer to the clinic and the health industry through public/private partnerships. The Carnot CALYM Institute coordinates and funds the CeVi_CART-T collection: a unique, perfectly annotated collection of cryopreserved viable human cells from lymphomas and reactive lymphoid tissues that federates 6 CALYM research units and their BRCs.
Constitution of a prospective cohort of patients receiving an allogeneic hematopoietic stem cell transplant
Evaluate the levels of biomarkers in the blood of patients at risk of transplant rejection or developing acute graft-versus-host disease after allogeneic transplant of hematopoietic stem cells or with pre-transplant deficits of hematopoietic stem cell proliferation.
Goals:
→ Establish a prospective cohort of patients receiving an allogeneic hematopoietic stem cell transplant and presenting post-transplant complications such as transplant rejection or acute graft-versus-host disease.
→ Establish a prospective cohort of patients with pre-transplant proliferation deficits of hematopoietic stem cells.
→ Validate the possibility of using predictive biomarkers of post-transplant complications with the objective to establish diagnostic test(s).
→ Study the relationship between certain biological mechanisms and stem cell proliferation deficits.
→ Validate the scientific rationale to establish new clinical protocols to test the potential of new treatment(s) for post-transplant complications such as prevention of transplant rejection, treating graft-versus-host disease or stem cell proliferation deficits.
The NI-0501-13 study in figures:
→ Total number of patients planned: 250
→ Number of partner centers in France: 12
Project leader, promoter and partner: Swedish Orphan Biovitrum (Sobi)
Investigators: CHU Angers, Hôpital universitaire Robert-Debré – AP-HP, Hôpital Saint-Louis – AP-HP, CHU Bordeaux, CHU Rennes, CHU Nancy, CHU Grenoble, CHU Clermont-Ferrand, CHU Montpellier (adult and pediatric units), CHU Caen, CHU Besançon.
Ancillary study of the Fibraplo clinical protocol
Test haploidentical transplantation in patients with primary or secondary myelofibrosis without a compatible related donor and assess disease-free and rejection-free survival one year after transplantation
Objectives :
→ Set up a biological resources collection from patients suffering from myelofibrosis and treated by hematopoietic stem cell transplantation
→ Show that haplo-identical transplant using thiotepa, fludarabin in combination with treosulfan gives acceptable results that could be better than an HLA donor transplant of which 9/10 did not match and close to a non-related compatible donor in patients with myelofibrosis.
Fibraplo in figures* :
→ Number of patients expected: 25
→ Number of patients included and sampled: 33
→ Number of samples available: 280
→ Number of partnering centers: 22
* as of 2023/08/31
Project coordinator : Dr Marie Robin, Service d’Hématologie Greffe, Hôpital Saint-Louis, AP-HP, Paris
Promotor : Assistance Publique – Hôpitaux de Paris (AP-HP)
Ancillary study of the GFM-DACORAL-DLI clinical protocol
Study of early administration of ASTX727 in combination with late infusions of donor lymphocytes after allogeneic hematopoietic stem cell transplantation in patients at very high risk of myelodysplastic syndrome or of acute myeloid leukemia
Objectives :
→ Set up a prospective cohort of patients with myelodysplastic syndrome or acute myeloid leukemia receiving the treatment provided for in the GFM-DACORAL-DLI clinical protocol
→ Show that early administration of ASTX727 in combination with late infusions of donor lymphocytes after allogeneic hematopoietic stem cell transplantation improves post-transplant survival
GFM-DACORAL-DLI in figures* :
→ Number of patients included and sampled: 59
→ Number of samples available: 612
→ Number of partnering centers: 16
* as of 2023/05/31
Project coordinator : Dr Marie Robin, Service d’Hématologie Greffe, Hôpital Saint-Louis, AP-HP, Paris
Promotor : Groupe Français des Myélodysplasies (GFM)
SHARE-4KIDS
Accelerating basic and translational research in pediatric oncology: helping to pool, structure and share research data
Objectives :
→ Help researchers to access public omics data by creating an open access patient/model repository for enrichment through global–omics characterization (genomics, transcriptomics, proteomics, methylome) of pediatric cancer models and patient samples.
Project coordinator : Dr Marie Castets, CNRS UMR5286 – INSERM UMR1052, Centre de Recherche en Cancérologie de Lyon (CRCL)
Promotor : React-4Kids network
Funder : INCa – PARPEDIA19-010
Ancillary study of the VANCALLO clinical protocol
Prevention of Clostridium difficile infections by oral vancomycin in patients undergoing allogeneic hematopoietic stem cell transplantation in a randomized, double-blind, placebo-controlled trial
Objectives :
→ Evaluate the efficacy of primary prophylaxis with oral vancomycin on the prevention of Clostridium difficile infections in patients hospitalized for an allogeneic hematopoietic stem cell transplantation
→ Assess the impact of primary prophylaxis with oral vancomycin on the risk factors for the onset of Clostridium difficile infection and on the composition of the intestinal microbiota
VANCALLO in figures* :
→ Number of patients included and sampled: 45
→ Number of samples available: 350
→ Number of partnering centers: 7
* as of 2023/08/31
Project coordinator : Dr Inès Boussen, Service d’hématologie clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris
Promotor : Assistance Publique des Hôpitaux de Paris (AP-HP)
Ancillary study of the TMF-Allo clinical protocol
Transplantation of Fecal Microbiota (FMT) in the prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation for hematological malignancy
Objectives :
→ Assess the impact of allogeneic FMT versus no treatment on the GRFS (Graft-versus-host disease-free, Relapse-Free Survival) rate at 1 year in patients treated with allograft with conditioning myeloablative therapy (MAC) for malignant hematologic disease
→ Assess the effects of FMT on hematological evolution, the incidence and severity of acute and chronic forms of graft-versus-host disease, and the evolution of infections
TMF-Allo in figures* :
→ Number of patients included and sampled: 11
→ Number of samples available: 91
→ Number of partnering centers: 19
* as of 2023/07/31
Project coordinator : Pr Jacques-Olivier Bay, Service de Thérapie Cellulaire et d’Hématologie Clinique Adulte, CHU de Clermont-Ferrand
Promotor : CHU de Clermont-Ferrand
